Literature DB >> 18245784

Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study.

Isabelle Le Ber1, Agnès Camuzat, Didier Hannequin, Florence Pasquier, Eric Guedj, Anne Rovelet-Lecrux, Valérie Hahn-Barma, Julie van der Zee, Fabienne Clot, Serge Bakchine, Michèle Puel, Mustapha Ghanim, Lucette Lacomblez, Jacqueline Mikol, Vincent Deramecourt, Pascal Lejeune, Vincent de la Sayette, Serge Belliard, Martine Vercelletto, Christian Meyrignac, Christine Van Broeckhoven, Jean-Charles Lambert, Patrice Verpillat, Dominique Campion, Marie-Odile Habert, Bruno Dubois, Alexis Brice.   

Abstract

Frontotemporal dementia (FTD), characterized by behavioural and language disorders, is a clinically, genetically and pathologically heterogeneous group of diseases. The most recently identified of the four known genes is GRN, associated with 17q-linked FTD with ubiquitin-immunoreactive inclusions. GRN was analysed in 502 probands with frontal variant FTD (fvFTD), FTD with motoneuron disease (FTD-MND), primary progressive aphasia (PPA) and corticobasal degeneration syndrome (CBDS). We studied the clinical, neuropsychological and brain perfusion characteristics of mutation carriers. Eighteen mutations, seven novel were found in 24 families including 32 symptomatic mutation carriers. No copy number variation was found. The phenotypes associated with GRN mutations vary greatly: 20/32 (63%) carriers had fvFTD, the other (12/32, 37%) had clinical diagnoses of PPA, CBDS, Lewy body dementia or Alzheimer's disease. Parkinsonism developed in 13/32 (41%), visual hallucinations in 8/32 (25%) and motor apraxia in 5/21 (24%). Constructional disorders were present in 10/21 (48%). Episodic memory disorders were frequent (16/18, 89%), consistent with hippocampal amnestic syndrome in 5/18 (28%). Hypoperfusion was observed in the hippocampus, parietal lobe and posterior cingulate gyrus, as well as the frontotemporal cortices. The frequency of mutations according to phenotype was 5.7% (20/352) in fvFTD, 17.9% (19/106) in familial forms, 4.4% in PPA (3/68), 3.3% in CBDS (1/30). Hallucinations, apraxia and amnestic syndrome may help differentiate GRN mutation carriers from others FTD patients. Variable phenotypes and neuropsychological profiles, as well as brain perfusion profiles associated with GRN mutations may reflect different patterns of neurodegeneration. Since all the mutations cause a progranulin haploinsufficiency, additional factors probably explain the variable clinical presentation of the disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18245784     DOI: 10.1093/brain/awn012

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  108 in total

Review 1.  RNA processing pathways in amyotrophic lateral sclerosis.

Authors:  Marka van Blitterswijk; John E Landers
Journal:  Neurogenetics       Date:  2010-03-27       Impact factor: 2.660

Review 2.  Biomarkers to identify the pathological basis for frontotemporal lobar degeneration.

Authors:  Murray Grossman
Journal:  J Mol Neurosci       Date:  2011-07-22       Impact factor: 3.444

3.  An algorithm for genetic testing of frontotemporal lobar degeneration.

Authors:  J S Goldman; R Rademakers; E D Huey; A L Boxer; R Mayeux; B L Miller; B F Boeve
Journal:  Neurology       Date:  2011-02-01       Impact factor: 9.910

Review 4.  Frontotemporal lobar degeneration: current knowledge and future challenges.

Authors:  Chiara Cerami; Elio Scarpini; Stefano F Cappa; Daniela Galimberti
Journal:  J Neurol       Date:  2012-04-25       Impact factor: 4.849

5.  Voxel-based morphometry patterns of atrophy in FTLD with mutations in MAPT or PGRN.

Authors:  J L Whitwell; C R Jack; B F Boeve; M L Senjem; M Baker; R Rademakers; R J Ivnik; D S Knopman; Z K Wszolek; R C Petersen; K A Josephs
Journal:  Neurology       Date:  2009-03-03       Impact factor: 9.910

6.  Circulating progranulin as a biomarker for neurodegenerative diseases.

Authors:  Roberta Ghidoni; Anna Paterlini; Luisa Benussi
Journal:  Am J Neurodegener Dis       Date:  2012-08-02

Review 7.  Neurodegenerative dementia and parkinsonism.

Authors:  A Gabelle; F Portet; C Berr; J Touchon
Journal:  J Nutr Health Aging       Date:  2010-01       Impact factor: 4.075

Review 8.  Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia.

Authors:  Edward D Huey; Nicole Armstrong; Parastoo Momeni; Jordan Grafman
Journal:  Expert Opin Ther Targets       Date:  2008-11       Impact factor: 6.902

9.  Progranulin (GRN) in two siblings of a Latino family and in other patients with schizophrenia.

Authors:  Parastoo Momeni; Karen DeTucci; Richard E Straub; Daniel R Weinberger; Peter Davies; Jordan Grafman; John Hardy; Edward D Huey
Journal:  Neurocase       Date:  2010-01-18       Impact factor: 0.881

10.  Partial deletions of the GRN gene are a cause of frontotemporal lobar degeneration.

Authors:  Fabienne Clot; Anne Rovelet-Lecrux; Foudil Lamari; Sandrine Noël; Boris Keren; Agnès Camuzat; Agnès Michon; Ludmila Jornea; Béatrice Laudier; Anne de Septenville; Paola Caroppo; Dominique Campion; Cécile Cazeneuve; Alexis Brice; Eric LeGuern; Isabelle Le Ber
Journal:  Neurogenetics       Date:  2014-01-28       Impact factor: 2.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.